Parkinsonian Disorders: Clinical Trials

645 trials for Parkinsonian Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

383 completed, 71 unknown, 56 terminated, 54 recruiting. 645 Phase 2, 107 Phase 1, 55 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2645Completed 383, Unknown 71, Terminated 56, Recruiting 54, Withdrawn 27, Active not recruiting 26, Not yet recruiting 22, Enrolling by invitation 4, Suspended 2
Phase 1107Completed 51, Recruiting 15, Unknown 11, Terminated 9, Active not recruiting 7, Not yet recruiting 7, Withdrawn 5, Enrolling by invitation 1, Suspended 1
Phase 355Completed 29, Unknown 8, Recruiting 7, Terminated 6, Withdrawn 5

Follow Parkinsonian Disorders: new trials by email Literature Review of Parkinsonian Disorders trials Research Report on Parkinsonian Disorders

Trials (filtered) newest first · largest first

All 645 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Terazosin And Metabolic Energetics in Parkinson's Disease
Terazosin 5 MG, Placebo - Parkinson's Disease (PD)
Phase 2SuspendedErgun Y. Uc1202028-07-012026-10-09
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
Gemfibrozil, Placebo - Parkinson Disease
Phase 2WithdrawnForest Hills Lab2027-11-012026-08-19
Terazosin for Dementia With Lewy Bodies
Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies
Phase 1 / Phase 2Not yet recruitingQiang Zhang402027-10-012026-03-12
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
MT101-5 - Parkinson's Disease
Phase 2Not yet recruitingMthera Pharma Co., Ltd.1202027-09-012026-10-16
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease
Formulation A, Formulation B, Formulation C - Healthy Volunteers
Phase 1 / Phase 2Not yet recruitingUniversity of Minnesota322027-04-012026-10-01
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
AB-1005 - Parkinson Disease
Phase 2Not yet recruitingBayer82027-01-252026-07-29
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Talineuren, Placebo - Parkinson Disease
Phase 2Not yet recruitingInnoMedica Schweiz AG402027-01-012026-10-30
Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study
Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), Advanced Primary PD
Phase 1 / Phase 2Not yet recruitingKanglin Biotechnology (Hangzhou) Co., Ltd.122027-01-012026-11-16
Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease
Sitagliptin, Sitagliptin placebo - Parkinson Disease
Phase 2Not yet recruitingYonsei University1602026-12-152026-09-10
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease
60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD)
Phase 2Not yet recruitingEnergenesis Biomedical Co., Ltd.1052026-12-012026-07-02
A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease
Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), PD
Phase 1 / Phase 2Not yet recruitingKanglin Biotechnology (Hangzhou) Co., Ltd.122026-12-012026-11-10
Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism
Intrathecal (IT), Intravenous - Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere
Phase 2Not yet recruitingBiocells Medical1202026-11-232026-03-13
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
RO7568282, Placebo - Parkinson's Disease
Phase 2RecruitingHoffmann-La Roche4742026-11-112026-11-16
Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)
Prescriptive Infusion Algorithm, AB-1005 - PARKINSON DISEASE (Disorder)
Phase 2Not yet recruitingAskBio Inc182026-11-012026-10-29
Lemborexant on Perioperative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep Brain Stimulation
Lemborexant 5 mg, Placabo - Parkinson Disease (PD), Sleep Initiation and Maintenance Disorders
Phase 2Not yet recruitingBeijing Tiantan Hospital1282026-11-012026-10-29
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
Prasinezumab, Sodium Chloride - Parkinson's Disease
Phase 2RecruitingUniversity Hospital Tuebingen1202026-10-012026-10-23
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy
Phase 1 / Phase 2RecruitingPrabesh Kanel152026-10-012026-11-05
DaxibotulinumtoxinA for Blepharospasm
Botulinum Neurotoxin Type A - Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid
Phase 2RecruitingUniversity of Pennsylvania202026-09-242026-09-29
Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease
UX-DA003 - Parkinson's Disease
Phase 1 / Phase 2RecruitingShanghai UniXell Biotechnology Co., Ltd122026-09-242026-11-04
RESvEraTrol in Parkinson's Disease (RESET)
Trans-Resveratrol - Parkinson's Disease
Phase 2RecruitingGeorgetown University302026-09-172026-09-18

Showing 20 of 645. Sign in to see all of them.

Narrower conditions

Parkinson Disease (603)  ·  Dyskinesias (44)  ·  Lewy Body Disease (37)  ·  Movement Disorders (33)  ·  Neurodegenerative Diseases (23)  ·  Dementia (17)  ·  Cognitive Dysfunction (15)  ·  Alzheimer Disease (14)  ·  Brain Diseases (13)  ·  Central Nervous System Diseases (12)  ·  Depression (12)  ·  REM Sleep Behavior Disorder (12)  ·  Tremor (10)  ·  Dyskinesia, Drug-Induced (9)

Broader conditions

Basal Ganglia Diseases (639)  ·  Nervous System Diseases (636)  ·  Central Nervous System Diseases (633)  ·  Brain Diseases (632)  ·  Synucleinopathies (630)  ·  Neurodegenerative Diseases (613)  ·  Movement Disorders (612)  ·  Pathological Conditions, Signs and Symptoms (106)  ·  Mental Disorders (94)  ·  Signs and Symptoms (86)  ·  Neurologic Manifestations (71)  ·  Neurocognitive Disorders (55)  ·  Dementia (33)  ·  Pathologic Processes (23)

Interventions

Levodopa (31)  ·  carbidopa, levodopa drug combination (23)  ·  Carbidopa (12)  ·  Apomorphine (10)  ·  Donepezil (8)  ·  istradefylline (8)  ·  mavoglurant (8)  ·  Sodium Chloride (7)  ·  entacapone (7)  ·  Pramipexole (6)  ·  perampanel (6)  ·  rotigotine (6)  ·  Ambroxol (5)  ·  Droxidopa (5)  ·  Saline Solution (5)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (21)  ·  Institute for Neurodegenerative Disorders (11)  ·  Chang Gung Memorial Hospital (8)  ·  Eisai Inc. (8)  ·  Axovant Sciences Ltd. (7)  ·  Biogen (6)  ·  Kyowa Kirin Co., Ltd. (6)  ·  Novartis (6)  ·  Tanta University (6)  ·  University College, London (6)  ·  University Hospital, Toulouse (6)  ·  Georgetown University (5)  ·  Impax Laboratories, LLC (5)  ·  Integrative Research Laboratories AB (5)  ·  Novartis Pharmaceuticals (5)

Countries

United States (318)  ·  France (70)  ·  United Kingdom (53)  ·  Germany (52)  ·  Canada (49)  ·  Italy (40)  ·  Spain (39)  ·  China (29)  ·  Japan (28)  ·  Israel (25)  ·  Poland (23)  ·  Netherlands (21)  ·  Austria (19)  ·  Sweden (16)  ·  Taiwan (16)

Top investigators

Danna Jennings, MD (6)  ·  Ilise Lombardo, MD (6)  ·  Fernando L Pagan, MD (4)  ·  Kyoji Imaoka, Mr (4)  ·  John G. Nutt, MD (3)  ·  Neil Sussman, MD (3)  ·  Abraham Lieberman, MD (2)

Results publications

PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 17941858, PMID 21484867, PMID 24412048, PMID 24711047, PMID 27214258, PMID 36849448, PMID 38072889, PMID 38706271, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12222941, PMID 12465055, PMID 12498954, PMID 12771261, PMID 12904089, PMID 1454205, PMID 15175402, PMID 15331239, PMID 15345186, PMID 15590952, PMID 15645531, PMID 15779234, PMID 15956161, PMID 16025231, PMID 16214880, PMID 16376913, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 17353373, PMID 17881719, PMID 17940108, PMID 18079166, PMID 18268187, PMID 18349024, PMID 18413464, PMID 18442107, PMID 18474731, PMID 18519872

NIH funding

2016 (6), 2023 (6), 2008 (4), 2015 (4), 2017 (4), 2009 (3), 2025 (3), 2018 (2), 2019 (2), R01NS021062 (2), R01NS099535 (2), U01NS043128 (2), 1UG3NS133515-01A1 (1), 2004 (1), 2005 (1)